Company intelligence / Profile preview
ExcellaBio
- Ownership
- Private
- Development stage
- Other
01
Overview
ExcellaBio has developed a patented process for manufacturing synthetic exosomes ("Bioxomes") that enables uniform particle size and scalable production. These Bioxomes mimic natural extracellular vesicles by delivering intracellular cargo such as nucleic acids or proteins into target cells. The technology aims to unlock new cell/gene therapy applications by providing safer alternatives to whole-cell therapies. No direct clinical results have been published yet—current status appears preclinical/platform-focused.
- Therapeutic areas
- GastroenterologyNeurologyDermatology
- Modalities
- Extracellular vesicle-based therapySynthetic exosome-based delivery systems ("Bioxomes")
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Orgenesis Inc.—collaboration/licensing agreement for commercializing the Bioxome™ technology globally.
Beyond the preview
Go deeper on ExcellaBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ExcellaBio.